Follicular Lymphoma
Conference Coverage
Susceptibility to 2nd cancers in WM/LPL survivors
PHILADELPHIA—A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM...
News
Inhibitor gets orphan designation for DLBCL
The US Food and Drug Administration (FDA) has granted orphan drug designation to CUDC-907 for the treatment of diffuse large B-cell lymphoma (...
News
Vitamin D levels linked to outcomes in FL
Vitamin D deficiency may negatively impact outcomes in patients with follicular lymphoma (FL), according to research published in the Journal of...
News
Pesticides may cause NHL, other cancers
Photo by John Messina The International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, has...
Conference Coverage
Maintenance prolongs PFS, not OS, in relapsed CLL
Credit: Linda Bartlett SAN FRANCISCO—Maintenance therapy with the anti-CD20 monoclonal antibody ofatumumab improves progression-free survival (PFS...
Conference Coverage
Approach can cure even high-risk FL, study suggests
The study showed that many patients transplanted in complete remission (CR) did not relapse and could be considered cured. Patients transplanted...
News
Autologous stem-cell transplant boosts survival in sequential transformed indolent lymphoma
Key clinical point: Autologous stem-cell transplantation (ASCT) plus chemo improved responses for patients with sequential indolent lymphoma...
Conference Coverage
Antibody shows activity in relapsed/refractory NHL
“It is encouraging to see results in an NHL study that selects a different target than CD20,” said Kristie Blum, MD, of The Ohio State University...
Conference Coverage
Ofatumumab maintenance halves risk of progression in relapsed CLL
Key clinical point: Maintenance ofatumumab cuts the risk of progression in half among patients with relapsed CLL. Major finding: Progression-free...
News
Drug gets orphan designation for MM & CLL/SLL
The European Medicines Agency (EMA) has granted orphan drug designation for selinexor (KPT-330) to treat multiple myeloma (MM) and chronic...